Market Scenario
The global duodenal cancer market is expected to grow slowly over the forecast period. It is estimated that the global duodenal cancer market is expected to register a CAGR ~ 3.2% during the forecast period of 2018–2023. Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine.
Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.
Segmentation
The global duodenal cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.
The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.
The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the global duodenal cancer market.
Browse for more details @ https://www.marketresearchfuture.com/reports/duodenal-cancer-market-6420
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment